Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr;100(4):652-665.
doi: 10.1002/ajh.27600. Epub 2025 Feb 4.

Biology and Management of Acute Myeloid Leukemia With Mutated NPM1

Evan C Chen  1 , Shai Shimony  1 , Marlise R Luskin  1 , Richard M Stone  1
Affiliations
Review

Biology and Management of Acute Myeloid Leukemia With Mutated NPM1

Evan C Chen et al. Am J Hematol. 2025 Apr.

Abstract

Mutations in nucleophosmin 1 (NPM1) are diseased-defining genetic alterations encountered in approximately one-third of cases of acute myeloid leukemia (AML). A mutation in NPM1 confers a more favorable prognosis; however, clinical outcomes of NPM1-mutated AML (NPM1 mut AML) are diverse due to the heterogeneity of disease biology, patient characteristics, and treatment received. Research over the last two decades has dramatically expanded our understanding of the biology of NPM1 mut AML and led to the development of new therapeutic approaches and strategies for monitoring measurable residual disease (MRD). Here, we review NPM1 mut AML with a practical focus on the current treatment landscape, the role of MRD in guiding management, and emerging therapies, including menin inhibitors.

Keywords: AML; AML‐molecular diagnosis & therapy; dysplasias; neoplasia‐myeloid leukemias.

PubMed Disclaimer

References

    1. L. Handschuh, P. Wojciechowski, M. Kazmierczak, et al., “NPM1 Alternative Transcripts Are Upregulated in Acute Myeloid and Lymphoblastic Leukemia and Their Expression Level Affects Patient Outcome,” Journal of Translational Medicine 16, no. 1 (2018): 232.
    1. B. Falini, I. Nicoletti, M. F. Martelli, and C. Mecucci, “Acute Myeloid Leukemia Carrying Cytoplasmic/Mutated Nucleophosmin (NPMc+ AML): Biologic and Clinical Features,” Blood 109, no. 3 (2007): 874–885.
    1. B. Falini, L. Brunetti, P. Sportoletti, and M. P. Martelli, “NPM1‐Mutated Acute Myeloid Leukemia: From Bench to Bedside,” Blood 136, no. 15 (2020): 1707–1721.
    1. B. Falini, C. Mecucci, E. Tiacci, et al., “Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia With a Normal Karyotype,” New England Journal of Medicine 352, no. 3 (2005): 254–266.
    1. M. P. Martelli, R. Rossi, A. Venanzi, et al., “Novel NPM1 Exon 5 Mutations and Gene Fusions Leading to Aberrant Cytoplasmic Nucleophosmin in AML,” Blood 138, no. 25 (2021): 2696–2701.

MeSH terms

LinkOut - more resources